Drug resistance and sensitivity of germ cell testicular tumors: Evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 3059-3064

  Eid, Hanna ^a   Géczi, Lajos ^a   Mágori, Aniko ^a   Bodrogi, Istvan ^a   Institoris, Etel ^a   Bak, Mihály ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Clinical relevance; MT; p53; Pgp

Indexed keywords

GLYCOPROTEIN P; METALLOTHIONEIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

ARTICLE; CANCER STAGING; DRUG RESISTANCE; DRUG SENSITIVITY; GERM CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TESTIS TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DRUG RESISTANCE, NEOPLASM; GERMINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METALLOTHIONEIN; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; P-GLYCOPROTEIN; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031841594     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Williams DS, Birch R, Einhom HL, Irwin L, Greco FA, Loehrer JP: Treatment of disseminated germ-cell tumors with cisplatin, Bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1453-1440, 1987.
2. Gottesman MM, Pasten I: Biochemistry of multidrug resistance mediated by the multi-drug transported. Annu Rev Biochem 62: 385-427, 1993.
3. Weinstein RS, Jakate SM, Dominguez JM, Lehovitz MD, Koukoulis GK, Klusense LF, Grogan TM, Saclarides TJ Roninson IB, Coon JS: relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991.
4. Bradley G, Sharma R, Rajalakshmi S, Ling V: P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 52: 5154-5161, 1992.
5. Pinedo HM, Giaccone G: P-glycoprotein - a marker of cancer-cell behavior. N Engl I Med 333: 1417-1419, 1995.
6. Hamer DH: Metallothionein . Annu Rev Biochem 55: 913-51, 1986.
7. Zeng J, Heuchel R, Schaffner W, Kagi JH: Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Spl. FEBSS Lett 279: 310-312, 1991.
8. Kelley SI, Basu A, Teicher BA, Hacker MP. Hamer DH and Lazzo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-15, 1988.
9. Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ, Ozols RF et al: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45: 416-22, 1990.
10. Murphy D, McGown AT, Crowther D, Mander A, Fox BW: Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer 63: 711-14, 1991.
11. Robson T, Hall A and Lohrer H: Increased sensitivity of a Chinese hamster ovary cell line to alhylating agents after overexpression of the human metallothionein II-A gene. Mutat Res 274: 177-185, 1992.
12. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
13. Callahan R: p53 mutations, another breast cancer prognostic factor. J Nad Cancer Inst 84: 826-827, 1992.
14. Lowe SW, Ruley HE, Jacks T and Houseman DE: p53-dependent apoptosis modulatges the cytotoxicity of anticancer agents. Cell 74: 957-968, 1993.
15. International Union Against Cancer (UIC-C): TNM classification of malignant tumours. 4th. New York: Springer-Verlag 1987.
16. Javadpour N: The role of biologic tumor markers in testicular cancer. Cancer 45: (Suppl): 1755-1761, 1980.
17. Mostofi FK, Sesterhenn IA, Davis CJ: World health organisation international histological classification of germ-cell tumours of the testis. In: Jones WG, Ward MA. and Anderson CK (eds.), Germ-cell tumours. II, 1-23. Pergamon, Oxford, 1986.
18. Monfardini S, Brunner K, Crowther D, Olive D, MacDonald J, Eckhardt S, et al: Manual of Cancer Chemotherapy, Third edition, UICC Technical Report Series 56: Geneva 1981.
19. Cattoretti G, Becker GM, Key G, Duchrow M, Schlüter C, Gall J, Gerd J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIBI and MIB3) detect proliferating cells in microwave-processed iormalin-fixed paraffin sections, Journal of pathology 168: 357-363, 1992.
20. Eid H, Bodrogi I, Csókay B, Oláh E, Bak M: Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression. Anticancer Research 16: 3447-3452, 1996
21. Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG: Metallothionein in testicular germ cell tumors and drug resistance. Cancer 72: 3029-3035, 1993.
22. Hall PA and Lane DP: p53 in tumour pathology: can we trust immunohistochernistry? -Revisited Journal of Pathology 172: 1-4, 1994
23. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53: 465-470,1993.
24. Katagari A, Tomita Y Nishiuama T Kimura M, Sato S: Immunohistochemichal detection of P-glycoprotein and GSTP-1 in testis cancer. Br J Cancer 68: 125-129, 1993.
25. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertion JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Pros Natl Acad Sci USA 86: 695-698, 1989.
26. Bak M, Efferth T, Mickisch G, Mattern J, Volm M: Detection of drug resistance and P-glycoprotein in human renal cell carcinomas. Eur Urol 17: 72-75, 1990.
27. Ramani P, Dewchand H: Expression of mdrl/P-glycoprotein and p1 1o in neuroblastoma. J Pathol 175: 13-27, 1995.
28. Bartkova J, Bartek J, Lukas J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CA, and Lane D: P53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int .I Cancer 49: 196-202,1991.
29. Lewis DJ, Sesterheen IA, McCarthy WF, Moul JW: Immunohistochemical expression of P53 tumor suppressor gene protein in adult GCTT: clinical correlation in stage I disease. J Urol (USA) 152: 418-423, 1994.
30. Eid H. Van der Looij M, Institoris E, Geczi L, Bodrogi I, Olah E, Bak M: Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer. Anticancer Res 17: 2663-2670, 1997b.
31. Lambkin HA, Mothersill CM, Kelehan P: Variations in immunohistochemical detection of p53 protein over-expression in cervical tumours with different antibodies and methods of detection. J Pathol 172: 13-18,1994.
32. Shuin T, Misaki H, Kubata Y, Yao M, Hosaka M: Differential expression of protooncogenes in human germ cell tumors of the testis. Cancer 73: 1721-1727,1994.
33. Kontozoglou TE, Baneriee D, Cherian MGG: Immunohistochemical localization of metallothionein in human testicular embryonal adenocarcinoma. Virchows Arch A Pathol Anat Histopathol 45: 545-9, 1989.
34. Eid H, Geczi L, Bodrogi I, Institoris E, Bak M: Do metallothioneins affect the response to treatment in testis cancers? J Cancer Res Clin Oncol 124: 31-36, 1998.
35. Kuczyk AM, Serth J Bokemeyer C, Allhoff EP, Jonassen J, Kuczyk S, Jonas U: P53 mutant gene expression in archival material of mature teratoma of the testis. Path Res Pract 190: 993-998, 1994.
36. Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J, Goss PE: Mutations of the p53 gene do not occur in testis cancer. Cancer Research 53: 3574-3578, 1993.
37. Strohmeyer TG, Fleishhacker M, Imai Y, Slamon DJ, Koeffler HP: Status of the p53 tumor suppressor gene and the MDM-2 gene in human testicular tumors: J Urol, part 2, 149: 311A, abstract 393, 1993.
38. Riou G, Barrois M, prost S, Terrier JM, Theodore C, Levine AJ: The p53 and mdm-2 Genes in Human testicular Germ-cell tumors. Molecular Carcinogenesis 12: 124-131, 1959.
39. Wei DY, Jiafu Z, Xi SQ, Yongjiang M, Xiulong Z, Daizong L and Jianren G: p53 gene mutation in Chinese human testicular seminoma. The Journal of Urology 150: 884-886, 1993.
40. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21, 1994.
41. Hainaut P, milner J: A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res 15: 1739-1742, 1993
42. Smith ML, Chen I, Zhan Q, O'Connor PM, Fornace AJ: Involvement of the p53 tumor suppressor in repair of W-type DNA damage. Oncogene, in press, 1995.
43. Fan S, Smith ML, Rivet II DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to Cisplatin and Pentoxifylline. Cancer Res 55: 1649-1654, 1995.
44. Hawking SD, Demers WG, Galloway AD: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer research 56:15: 892-898, 1996.
45. Volm M, J Mattern: Immunohistochemical detection of p53 in non-small-cell lung cancer (letter). J Natl Cancer Inst 86: 1249, 1994.
46. Soo Lee J, Yoon A, Kalapurakal KS, Ro YJ, Lee J, Tu N, Hittelman NV, Hong KW: Expression of p53 oncoprotein in Non-Small-Cell Lung Cancer. J Clin Oncol 13: 1893-1903, 1995.
47. Kyritsis PA, Bondy LM, Hess RK, Cunningham EJ, Zhu D, Amos TC, Tung Levin AV, Bruner MJ: Prognostic significance of pS3 immunoreactivity in patients with glioma. Clin Cancer Res 1: 1617-1622, 1995.
48. Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462, 1992.
49. Wosikowski K, Regis JT, Rebey RW: Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth and Differ 6: 1395-1403, 1995.
50. Kant Ed, Heide I, Thiede C, Herrmann R, Rochlitz FC: MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. J Cancer Res Clin Oncol 122: 671-675, 1996.